February 2nd 2024
"This study identifies a new target for VTE prevention," writes Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.
September 13th 2023
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Uro Pipeline: FDA accepts biologics license application for bladder Ca agent
January 13th 2017Other pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
Uro Pipeline: FDA committee votes in favor of nocturia treatment approval
November 1st 2016Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
Placement of a hydrogel rectal spacer before RT for prostate Ca
April 1st 2016Many approaches have been tried for reducing the rectal toxicity of radiotherapy (Radiat Oncol 2013; 8:96; Int J Radiat Oncol Biol Phys 2012; 82:1918-22; Radiat Oncol 2014; 9:96). This article discusses a newer therapy that involves the injection of a temporary hydrogel in the plane between the prostate and rectum.